We tested whether combining p-tau217 and GFAP together and with other plasma AD biomarkers (Aβ42/40, NfL, t-tau) and age (a strong predictor of AD pathological changes in DS25) could further improve their discriminative accuracy for tau-PET and Aβ-PET status. The gene discussed is GFAP; the disease is Alzheimer disease.